ChemicalBook > Product Catalog >API >Circulatory system drugs >Anti-Congestive Heart Failure drugs >DIGOXIN

DIGOXIN

DIGOXIN Basic information
Product Name:DIGOXIN
Synonyms:Digoxin 20830-75-5;(3beta,5beta,12beta)-3-((o-2,6-dideoxy-beta-d-ribo-hexapyranosyl-(1-4)-2,6-dide;-12,14-dihydroxycard-20(22)-enolide;14-dihydroxy-,(3beta,5beta,12beta)-xopyranosyl)oxy]-1;14-dihydroxy-,(3beta,5beta,12beta)-y)-1;-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1.fwdarw.)-2,6-dideoxy-beta-d-ribo-he;dixina;dokim
CAS:20830-75-5
MF:C41H64O14
MW:780.94
EINECS:244-068-1
Product Categories:Organics;Biochemistry;Glycosides;Steroidglycosides;Steroids;Sugars;Trisaccharides;Intermediates & Fine Chemicals;Pharmaceuticals;ATPase;Carbohydrates & Derivatives;Steroid;API;Carbohydrates & Derivatives, Pharmaceuticals, Intermediates & Fine Chemicals, Steroid;LANOXIN;Inhibitors
Mol File:20830-75-5.mol
DIGOXIN Structure
DIGOXIN Chemical Properties
Melting point 248 °C
alpha 25Hg +13.4 to 13.8° (c = 10 in pyridine)
Boiling point 661.93°C (rough estimate)
density 1.1110 (rough estimate)
refractive index 12 ° (C=10, Pyridine)
Fp 9℃
storage temp. Refrigerator
solubility Soluble in dimethyl sulfoxide and methanol.
pka13.50±0.70(Predicted)
form powder
Water Solubility 46.08mg/L(room temperature)
Merck 14,3167
BRN 77011
CAS DataBase Reference20830-75-5
EPA Substance Registry SystemDigoxin (20830-75-5)
Safety Information
Hazard Codes T,T+,F
Risk Statements 25-26/27/28-23/25-39/23/24/25-23/24/25-11-28-26
Safety Statements 22-36/37/39-45-36/37-16-28A
RIDADR UN 3462 6.1/PG 2
WGK Germany 3
RTECS IH6125000
3-10
TSCA Yes
HazardClass 6.1
PackingGroup II
HS Code 29389090
Hazardous Substances Data20830-75-5(Hazardous Substances Data)
MSDS Information
ProviderLanguage
SigmaAldrich English
ALFA English
DIGOXIN Usage And Synthesis
Chemical PropertiesWhite Crystalline Powder
Usescardiac stimulant
UsesCardiotonic
DefinitionChEBI: A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.
Brand nameLanoxin (GlaxoSmithKline).
General DescriptionClear to white crystals or white crystalline powder. Odorless. Used as a cardiotonic drug.
General DescriptionDigitalis (Crystodigin) is isolated fromD. lanata and D. purpurea among other Digitalis spp., and isthe chief active glycoside in digitalis leaf, with 1 mg digitoxinequal to 1 g of digitalis leaf therapy. In patients who missdoses, digitalis is very useful for maintenance therapy becauseof the longer half-life it provides. The longer durationand increased half-life are a result of the lack of the C-12hydroxy that is present in digoxin. In digoxin, this hydroxyplays two roles: (a) it serves as a site for metabolism, whichreduces the compound’s half-life; and (b) it gives more hydrophiliccharacter, which results in greater water solubilityand ease in renal elimination.
General DescriptionDigoxin (Lanoxin) is a purified digitalis preparationfrom D. lanata and represents the most widely useddigitalis glycoside. This wide use is primarily a result of itsfast onset and short half-life. Position 3 of the steroid is substitutedwith three digitoxose residues that, when removed,provide a genin or aglycone steroid that is still capable of receptorbinding but with altered pharmacokinetics.
Health HazardMaterial is a digitalis glycoside. Ingestion can cause death. Material is considered super toxic; probable human oral lethal dose is less than 5 mg/kg, a taste (less than 7 drops) for a 70 kg (150 lb.) person. Persons at risk include those taking drugs for thyroid and renal diseases. Quinidine and diuretics taken concurrently with DIGOXIN can be hazardous. It should be used with extreme care during pregnancy and in nursing mothers.
Fire HazardAvoid light.
Safety ProfileA deadly poison by most routes. Human systemic effects by ingestion: anorexia, cardlac arrhythmias, nausea and vomiting, visual field changes, pulse rate decrease, fall in blood pressure. An experimental teratogen. When heated to decomposition it emits acrid and irritating fumes. See also DIGITALIS.
Purification MethodsCrystallise digoxin from aqueous EtOH, aqueous pyridine, EtOH/CHCl3, and dry it in a vacuum at 100o. The melting point depends on heating rate, but when placed in a bath at 260o and heated slowly it decomposes at 265o. In EtOH it has max at 220nm ( 12,800). [Smith J Chem Soc 508 1930, X-ray: Go et al. Cryst Struct Commun 8 149, 1031 1979, Beilstein 18/4 V 381.] HIGHLY TOXIC.
DIGOXIN Preparation Products And Raw materials
Tag:DIGOXIN(20830-75-5) Related Product Information
Digitalis Glycosides digoxin-16'-glucuronide digoxin-like factors DIGOXIN [3H(G)] MOUSE MONOCLONAL ANTI-DIGOXIN-BIOTINCONJ UGATE, CLO DIGOXIN HRP Digitalis lutea australis, ext. digoxin 2-methyl-4-(4-nitrobenzyl)perhydro-1,4-oxazepine Digoxin, 4'''-O-methyl- (8CI) ALPHA-ACETYLDIGOXIN 16-Formyldigitalinum verum DIGOXIN-D3 Deslanoside lanatoside D DIGOXIN BETA-ACETYLDIGOXIN Methyl-Digoxin,alpha Digoxin, teraacetate